

Appeninn

Recommendation: Accumulate

Target price 12M: HUF 743

EUR ths	2018 H1	2017 H1	Ch (%)
Gross rental Income (GRI)	2,700	2,604	4%
Clean EBITDA	955	1,718	-44%
EBIT	944	718	31%
Profit	723	-37	-2055%
FFO1	376	874	-57%
EBITDA margin [%]	35%	66%	-31pps
LTV	54%	64%	-10pps
Gross Asset Value (GAV)	87,408	64,561	36%



Share price close as of 01/10/2018	HUF 580	Bloomberg	APPENINN HB
Number of shares [million]	47.4	Reuters	
Market capitalization [HUF bn/EUR mn]	27 / 88	Free float	42%
Daily turnover 12M [EUR th]	104	52 week range	HUF 442-1,170

In a transitory period...

- Large administrative costs and personel expenses took its toll on Appeninn's financial figures in H1, but our full year EBITDA forecast is still easily achievable, in our view.
- Numbers were heavily distorted, because large part of the announced acquisitions closed only after H1 (SPAR asset and other two properties), thus income from those assets are missing from H1 report, but transaction & administrative costs (+106% y-o-y; +EUR 260m) and personel expenses (+EUR 329m vs. EUR 1.4m last year) have already been incurred.
- Although profit turned to black (EUR 723m) from red (EUR - 37m) in a year, it was solely due to the missing large revaluation loss (EUR 1 billion) that occurred in 2017 H1. On the operation side, Appeninn posted a EUR 955 ths clean EBITDA in H1, significantly lower (-44% y-o-y) compared to last year's same period. The reasons are the followings:
 1. Elevated personel cost which has skyrocketed from EUR 1,400 to EUR 329,000 as the number of employees increased from 1 to 18 (Appeninn also appointed new CEO, and deputy CEO as well).
 2. Administrative cost has also climbed substantially partly due to the many corporate events in H1 (+106% y-o-y; +EUR 260,000).

In a nutshell, temporary elevated cost resulting from acquisition cost is part of the growth story in our view, which expenses later on should disappear as Appeninn reaches its desired size (GAV).

Equity Analyst:

Gellert Gaal
+361 489 2228
g.gaal@con.hu

50 Alkotás Street,
Budapest
www.con.hu

- According to the H1 report, Gross Asset Value (GAV) increased by EUR 22 million reaching EUR 87 million, which should further grow in H2 to EUR 101 million as recent acquisitions closes. In the first half year, Appeninn acquired 20 properties and disposed three assets, in our understanding. As a result of portfolio optimization, leverage moderated to LTV 54% vs. 64%.
- Below EBIT, interest expense decreased significantly by 25% to EUR 470,000 from EUR 634,000 a year ago level, thanks to the refinancing of the liabilities at a lower interest rates ca. 100 bps lower on our calculations. Furthermore, thanks to favourable FX movement Appeninn booked EUR 359,000 unrealized gain.
- Funds From Operations (FFO) figure dropped below EUR 400,000 implying a ca. 57% decrease from EUR 874,000 as result of low margin (EBITDA margin 35% vs. 65% last y-o-y) in a year.
- **Opinion:** Although the significant OPEX inflation heavily deteriorated Appeninn financial performance in H1, low EBITDA margin is only temporary, in our view. Revenue from SPAR and two other assets (Andrássy u. 59 and Andrássy u. 105) will support revenue in H2 (+EUR 2.4 million vs current EUR 2.7 million) and also costs related acquisitions should also disappear, enhancing the current 35% EBITDA margin.

Appeninn provided a pro forma figure in order to show how the financials would have evolved if all of the transactions were to be closed before 2018.01.01. (*see our P&L table below*). This theoretical set of numbers show similar characteristics to our earnings model assumptions (ie. 65% EBITDA margin).

Using these pro forma EBITDA numbers (ie. EUR 2.2 million EBITDA would have come from the assets in H1 report according to Appeninn) and assuming similar performance for the rest of the portfolio in H2, Appeninn's full year EBITDA should arrive to EUR 4.1 million slightly above our EUR 4 million forecast. In light of the underlying operation we maintain our target price and recommendation.

Eventful H1

- We gathered the meaningful corporate events that have occurred with Appeninn since our initiation of coverage:
 1. Retail portfolio expansion has begun. Appeninn announced three transactions regarding the expansion of its retail portfolio, one is a real estate in Miskolc and two plots in Eger and Batorbágy. Also the company secured long term rental contracts for those properties with ALDI. Appeninn's strategy is to develop ca. 90,000 sqm retail portfolio across Hungary, this growth seems to unfold with these announcements.
 2. Company acquired large plots in Balatonvilágos which could be used to developing touristic related properties and at the same time in line with its strategy to develop ca. 90,000 sqm single tenant units. However, as this direction (eg. touristic related development) is relatively new and management has not announced any modification of the latest strategy, we have not incorporated this business line in our model. Nonetheless, as almost every touristic related statistics in the Balaton region have been increasing, the new direction is encouraging.
 3. BDPST Group purchased ca. 21% stake in Appeninn from Konzum.
 4. Gábor Tomcsányi CEO and Somfalvi Péter deputy CEO joined the management team in august. As both of them has large experience in the real estate market, we expect that the strategy implementation should be gain new dynamic.

- **Market outlook: Investment attitude towards Budapest's Real Estate (RE) market continues to be strong.** Foreign companies remain on the buy side for both office and retail assets in Budapest. To give an example, in mid-September GTC announced an office acquisition (35k sqm) on Váci corridor. On the retail side, NEPI ROCKCASTLE also showed its unfaltering confidence in Budapest RE market and after purchasing Arena plaza (largest shopping centre) they acquired a controlling stake in Mammut as well.

- **Opinion:** Although the significant cost inflation heavily deteriorated Appeninn financial performance in H1, low EBITDA margin is only temporary, in our view. Revenue from SPAR and two other assets (Andrássy u. 59 and Andrássy u. 105) will support revenue in H2 (+EUR 2.4 million) and also costs related acquisitions should also disappear, enhancing the current 35% EBITDA margin.

Appeninn provided a pro forma figure in order to show how the financials would have evolved if all of the transactions were to be closed before 2018.01.01. (see our P&L table below). This theoretical set of numbers show similar characteristics to our earnings model assumptions (eg. 65% EBITDA margin).

Using these pro forma EBITDA numbers (ie. EUR 2.2 million EBITDA would have come from the assets in H1 report according to Appeninn) and assuming similar performance for the rest of the portfolio in H2, Appeninn's full year EBITDA should arrive to EUR 4.1 million slightly above our EUR 4 million forecast. **In light of the underlying operation we maintain our target price and recommendation.**

ACTUAL AND PRO FORMA PROFIT AND LOSS [EUR THS]

EUR ths	2018 H1	2017 H1	diff (%)	2018 Pro Forma	diff to 2017 H1 (%)
Gross rental income (GRI)	2.700	2.604	4%	5.098	96%
Net rental income (NRI)	1.751	1.867	-6%	4.149	122%
Administrative costs	- 504	- 244	107%	- 504	107%
Personel costs	- 329	- 1	23429%	- 329	23429%
Other income / expenses	48	507	-91%	48	-91%
Revaluation gain / loss		- 1.000		-	-100%
Capex expenses	- 11	- 410	-97%	- 11	-97%
EBITDA	955	718	33%	3.353	367%
DD&A	- 11	-		- 11	
EBIT	943	718	31%	3.341	365%
Net financials	- 111	- 727	-85%	- 111	-85%
EBT	833	- 9	-9053%	3.231	-34838%
Tax	- 110	- 28	287%	- 350	1131%
Profit	723	38	-2017%	2.881	-7742%
EBITDA margin	35%	28%		66%	
LTV	54%	64%		60%	

Source: Appennin, Concorde

RESEARCH DISCLOSURE

Concorde Securities Ltd. does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interests that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For analysts certification and other important disclosures, please refer to the “Disclaimer” section at the end of this report.

DISCLAIMER 1.

This research report has been prepared by Concorde Securities Ltd., a full-service Hungarian investment banking, investment management and brokerage firm. Concorde Securities Ltd. is under the supervision of the National Bank of Hungary in its capacity as financial supervisory authority.

Concorde Securities Ltd. is registered in Hungary and does not have any subsidiaries, branches or offices outside of Hungary. Therefore we are not allowed to provide direct investment banking services to US investors and restrictions may apply to our potential investment banking services according to your country’s jurisdiction. For important disclosures to U.S. investors, please refer of the “Notice to U.S. Investors” section at the end of this Disclaimer.

Our salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are their own and may be contrary to the opinions expressed in our research products, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed by our analysts or traders.

Our research, sales and trading professionals are paid based on the profitability of the respective divisions of Concorde Securities Ltd., which from time-to-time may include revenues from the firm’s capital market activity. Concorde Securities Ltd. does not prohibit analysts, salespeople and traders from maintaining a financial interest in the securities or futures of any companies that they cover or trade on their clients’ behalf in strict compliance with the Hungarian Capital Markets Act.

ANALYSTS CERTIFICATION

The research analysts undersigned and responsible for the preparation of this report hereby certify that (i) the views expressed in this research report accurately reflect their personal views about any and all of the securities or issuers referred to in this research report; (ii) no part of the analysts’ compensation was, is or will be directly or indirectly related to the specific recommendation or views expressed in this report and (iii) no part of their compensation is tied to any specific investment transactions performed by Concorde Securities Ltd.

Name and job title of individuals involved in the production of this report are disclosed at the end of this report.

Concorde Securities Ltd. is a leading manager and underwriter of Hungarian equity offerings. We have investment banking and other business relations with a substantial percentage of the companies traded on the Budapest Stock Exchange and covered by our research department. Concorde Securities Ltd, its directors and employees may have a position in these securities, which may change at any time.

Concorde Securities Ltd. acted as Lead Manager of the private and public share placement of the shares of FHB in 2003, Masterplast in 2012 and Duna House in 2016. Concorde Securities Ltd. acted as the Co-lead Manager of Gedeon Richter’s exchangeable bond issue in September 2004. Concorde Securities Ltd. has provided financial advice to Magyar Telekom.

EXPLANATION OF RATINGS AND METHODOLOGY

Rating	Trigger
Buy	Total return is expected to exceed 20% in the next 12 months
Accumulate	Total return is expected to be in the range of 10-20%
Neutral	Total return is expected to be in the range of 10%-(-10%)
Reduce	Total return is expected to be in the range of -10-(-20%)
Sell	Total return is expected to be lower than -20%
Under Revision	The stock is put Under Revision if covering analyst considers new information may change the valuation materially and if this may take more time.
Coverage in transition	Coverage in transition rating is assigned to a stock if there is a change in analyst.

Securities prices:

Prices are taken as of the previous day's close on the home market unless otherwise stated.

Valuations and risks:

Analysis of specific risks to set stock target prices highlighted in our investment case(s) are outlined throughout the report. For details of methodologies used to determine our price targets and risks related to the achievement of the targets referred to in the main body of the report or at [Rating Methodology](https://www.con.hu/wp-content/uploads/2016/04/Methodology_concorde_research.pdf?tstamp=201710021038) on our website. (https://www.con.hu/wp-content/uploads/2016/04/Methodology_concorde_research.pdf?tstamp=201710021038)

Research disclosures:

Concorde Securities Ltd. may have published other investment recommendations in respect of the same securities/instruments recommended in this report during the preceding 12 months. Disclosure of previous investment recommendations produced by Concorde Securities Ltd. in the previous 12 months can be found at [Rating history](https://www.con.hu/wp-content/uploads/2016/04/Rating-history.pdf?tstamp=201710021038). (<https://www.con.hu/wp-content/uploads/2016/04/Rating-history.pdf?tstamp=201710021038>)

GENERAL

This report is provided for information purposes only and does not represent an offer for sale, or the solicitation of any offer to buy or sell any securities.

The information, and any opinions, estimates and forecast have been obtained from sources believed by us to be reliable, but no representation or warranty, express or implied is made by us as to their accuracy or completeness. The information, opinions, estimates and forecasts may well be affected by subsequent changes in market conditions. This document may not be reproduced in whole or in part, or published for any purpose.

REPRODUCTION OR REBROADCAST OF ANY PORTION OF THIS RESEARCH REPORT IS STRICTLY PROHIBITED WITHOUT THE WRITTEN PERMISSION OF CONCORDE SECURITIES LTD.

NOTICE TO US INVESTORS

This report was prepared, approved, published and distributed Concorde Securities Ltd. located outside of the United States (a "non-US Group Company"). This report is distributed in the U.S. by LXM LLP USA, a U.S. registered broker dealer, on behalf of Concorde Securities Ltd. only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act")) pursuant to the exemption in Rule 15a-6 and any transaction effected by a U.S. customer in the securities described in this report must be effected through LXM LLP USA.

Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization.

Analyst Certification. Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report. Please bear in mind that (i) Concorde Securities Ltd. is the employer of the research analyst(s) responsible for the content of this report and (ii) research analysts preparing this report are resident outside the United States and are not associated persons of any US regulated broker-dealer and that therefore the analyst(s) is/are not subject to supervision by a US broker-dealer, and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Important US Regulatory Disclosures on Subject Companies. This material was produced by Concorde Securities Ltd. solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. It is distributed in the United States of America by LXM LLP USA and elsewhere in the world by Concorde Securities Ltd. or an authorized affiliate Concorde Securities Ltd. This document does not constitute an offer of, or an invitation by or on behalf of Concorde Securities Ltd. or its affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which Concorde Securities Ltd. or its Affiliates consider to be reliable. None of Concorde Securities Ltd. accepts any liability or responsibility whatsoever for the accuracy or completeness of any such

information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions.

LXM LLP USA assumes responsibility for the research reports content in regards to research distributed in the U.S. LXM LLP USA or its affiliates has not managed or co-managed a public offering of securities for the subject company in the past 12 months, has not received compensation for investment banking services from the subject company in the past 12 months, does not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next 3 months. LXM LLP USA has never owned any class of equity securities of the subject company. There are not any other actual, material conflicts of interest of LXM LLP USA at the time of the publication of this research report. As of the publication of this report LXM LLP USA, does not make a market in the subject securities.

DISCLAIMER 2.

This research/commentary was prepared by the assignment of Budapest Stock Exchange Ltd. (registered seat: 1054 Budapest, Szabadság tér 7. Platina torony I. ép. IV. emelet; company registration number: 01-10-044764, hereinafter: BSE) under the agreement which was concluded by and between BSE and Concorde Securities Ltd. (registered seat: H-1123 Budapest Alkotás utca 50., company registration number: 01-10-043521, hereinafter: Investment Service Provider)

BSE shall not be liable for the content of this research/commentary, especially for the accuracy and completeness of the information therein and for the forecasts and conclusions; the Service Provider shall be solely liable for these. The Service Provider is entitled to all copyrights regarding this research/commentary however BSE is entitled to use and advertise/spread it but BSE shall not modify its content.

This research/commentary shall not be qualified as investment advice specified in Point 9 Section 4 (2) of Act No. CXXXVIII of 2007 on Investment Firms and Commodity Dealers and on the Regulations Governing their Activities. Furthermore, this document shall not be qualified as an offer or call to tenders for the purchase, sale or hold of the financial instrument(s) concerned by the research/commentary.

Sales:

Eva Kormendi, CFA Tamas Hegedus
 +36 1 489 2340 + 36 1 489 2388
e.kormendi@con.hu t.hegedus@con.hu

Trade:

Steve Simon Peter Rimar Gyorgy Sugar
 +36 1 489 2335 +36 1 489 2230 +36 1 489 2231
i.simon@con.hu p.rimar@con.hu gy.sugar@con.hu

SUMMARY OF CONCORDE'S RECOMMENDATIONS

